Posted by Doug Wharley on Mar 5th, 2026
Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product Jelmyto, and a strengthened balance...
More of this article »